Business
Distribution Agreement with AnthroTronix
Distribution Agreement with AnthroTronix.
About this update from Cambridge Cognition Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 9679Z Cambridge Cognition Holdings PLC 02 June 2016 \n\n2nd June 2016\nCambridge Cognition Holdings Plc\n('Cambridge Cognition' or the 'Company')\n \nDistribution agreement with AnthroTronix\n \nThe neuroscience technology company Cambridge Cognition Holdings PLC (Cambridge, UK - LSE: COG), which develops and markets products and technologies for near-patient cognitive assessment, has agreed a reseller distribution agreement with US engineering research and development company AnthroTronix Incorporated for the AnthroTronix brain health assessment product, DANA™.\nDANA software measures and monitors subtle and acute changes in cognitive efficiency on handheld devices to support medical rehabilitation. Initially funded by the United States Department of Defense to evaluate performance degradation in military personnel, DANA was granted FDA clearance in 2014 for use by medical providers to aid in the assessment of an individual's medical or psychological state.\nCognitive and behavioural health is a growing area of military research. In 2013 the U.S. Veterans Affairs Department spent approximately $122 million on behavioural health research, of which $30 million focused on PTSD. Under the terms of the reseller agreement, Cambridge Cognition now has rights to distribute the DANA product to European military organisations and occupational health providers in addition to its core academic research and pharmaceutical clinical trials markets.\nThe market for brain training and cognitive assessments is approximately $1.3 billion worldwide and is forecast to exceed $6 billion by 2020.\nCambridge Cognition will commence marketing in the USA immediately and in Q4 2016 in Europe once the product has received CE mark registration.\nDr. Corinna Lathan, Board Chair and Chief Executive Officer, AnthroTronix commented:\n\"Monitoring brain health and cognitive function should be a part of an integrated approach to one's health and well-being. Our mobile medical app DANA is a unique tool that is proven to effectively and efficiently track changes in cognitive function over time. This agreement with Cambridge Cognition will help us expand DANA's reach throughout Europe and the United States.\"\nDr. Steven Powell, Chief Executive Officer, Cambridge Cognition:\n\"We are delighted to have agreed this reseller agreement...